TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8457050
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml 2% lidocaine, followed by 10 ml every 45 min (Control)
Study: 8457050
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of 3% chloroprocaine (containing EDTA), plus 5 ml every 45 min
Study: 8457050
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 3% chloroprocaine plus 10 ml every 45 min
Study: 8457050
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 3% chloroprocaine (containing metabisulfite as the preservative but no EDTA) plus 10 ml every 45 min
Study: 8457050
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 3% chloroprocaine with the pH adjusted to 7.3, plus 10 ml every 45 min
Study: 3836297
Drug: Labetalol (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (100, 200, 400, 600 mg BID)
Study: 3836297
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 or 50 mg BID)
Study: 12847531
Drug: 2-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day antibiotic therapy (AT)
Study: 12847531
Drug: 4-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day antibiotic therapy (AT)
Study: 10584976
Drug: Intravenous Zofran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Zofran
Study: 8884403
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy with mothers present
Study: 8884403
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy without mothers present
Study: 31007170
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (5 mL applied topically to the cervix 5 minutes prior to paracervical blockade)
Study: 29318656
Drug: Finasteride (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (an androgen bioactivation inhibitor)
Study: 26961599
Drug: Meals supplemented
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meals supplemented with 1.4 g of cocoa extract (645 mg polyphenols)
Study: 24743880
Drug: Post-febrile malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-febrile malaria treatment
Study: 22992045
Drug: Influenza A
Normalized name: influenza A virus
DrugBank: Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) (DB14444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza A H1N1/2009 vaccine
Study: 11978262
Drug: Oat cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat cereal group (5.52 g/day beta-glucan)
Study: 11978262
Drug: Low-fiber cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber cereal control group (less than 1.0 g/day total fiber)
Study: 8534671
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg daily simvastatin, 20 mg daily simvastatin, Matching placebo
Study: 389264
Drug: Ibuprofen (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1600 mg daily) and soluble aspirin (3.6 g daily)
Study: 389264
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg daily) and soluble aspirin (2.4 g daily)
Study: 389264
Drug: Ibuprofen (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (single drug period)
Study: 389264
Drug: Salicylate (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylate (single drug period)
Study: 389264
Drug: Concurrent salicylate
Normalized name: salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent salicylate administration
Study: 28605609
Drug: VPRO (CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPRO (CHO 75 g, protein 25 g, vitamins D3 5000 IU, K2 1000 μg)
Study: 28605609
Drug: PRO (CHO
Normalized name: Vital E- Repro (cholecalciferol 100000 UNT/ML / vitamin A 200000 UNT/ML / vitamin E 300 UNT/ML) Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO (CHO 75 g, protein 25 g, no vitamins)
Study: 22143664
Drug: Digital radiographs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital radiographs with full dose
Study: 22143664
Drug: Digital radiographs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital radiographs with reduced dose
Study: 19553594
Drug: Active migraine
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active migraine with frequency < monthly
Study: 19553594
Drug: Active migraine
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active migraine with frequency monthly
Study: 19553594
Drug: Active migraine
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active migraine with frequency >or= weekly
Study: 19553594
Drug: Active migraine
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active migraine with aura and frequency < monthly
Study: 19553594
Drug: Active migraine
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active migraine with aura and frequency >or= weekly
Study: 3058919
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulfate (20 mg elemental zinc twice daily)
Study: 3058919
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulfate (20 mg elemental zinc twice daily) in subjects with severe initial zinc depletion
Study: 28429377
Drug: Olfactory training
Normalized name: BOS TAURUS OLFACTORY BULB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olfactory training (OT) group, daily olfactory exposure for 5 months
Study: 28429377
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, daily Sudoku problems for 5 months
Study: 27923410
Drug: Brazil nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nuts (approximately 48 µg/d as six Brazil nuts)
Study: 27923410
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) capsules (four GTE capsules, 800 mg (‐)‐epigallocatechin‐3‐gallate)
Study: 27923410
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Brazil nuts and GTE
Study: 25339632
Drug: Integrated management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated management (daily contact with monitoring centre using handheld PDA)
Study: 23525414
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 81 mg daily
Study: 18334143
Drug: Hirudin-treated group
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin-treated group (peroral administration of Maixuekang capsules)
Study: 18334143
Drug: Dipyridamole-treated group
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole-treated group (peroral administration of dipyridamole)
Study: 12911866
Drug: 60% honey
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60% honey solution inhalation
Study: 12911866
Drug: Distill water
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distill water inhalation
Study: 12911866
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose inhalation
Study: 11313239
Drug: Peripheral blood
Normalized name: Peripheral blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood stem cell (PBSC) donors treated with 5 to 7 days of filgrastim at a dose of 16 microg/kg/d and underwent 1 to 3 days of apheresis to obtain 5 x 10(6) CD34(+) cells per kilogram recipient weight.
Study: 8195519
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation (treatment group)
Study: 3298383
Drug: L-Cystine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Cystine and Pyridoxine Hydrochloride combination (in addition to classical post-operative treatment)
Study: 3298383
Drug: Classical post-operative
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical post-operative treatment (control group)
Study: 28133772
Drug: FKB327 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: FKB327 (40 mg)
Study: 28133772
Drug: EU-Humira (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-Humira (40 mg)
Study: 28133772
Drug: US-Humira (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-Humira (40 mg)
Study: 25870124
Drug: Combination B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination B (Red yeast rice (Monakolin K 3.3 mg), Berberine 531.25 mg and leaf extract of Morus alba)
Study: 25870124
Drug: Combination A
Normalized name: SUNFLOWER OIL 7.92 g in 14 g TOPICAL STICK [OrgaPlus Super Care Balm for combination and oi ly skin type 14g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination A (Policosanol, Red yeast rice (Monakolin K 3 mg), Berberine 500 mg, Astaxantine, Folic Acid and Coenzyme Q10)
Study: 25870124
Drug: Combination A
Normalized name: SUNFLOWER OIL 7.92 g in 14 g TOPICAL STICK [OrgaPlus Super Care Balm for combination and oi ly skin type 14g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination A and Combination B
Study: 25870124
Drug: Combination B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination B
Study: 21248446
Drug: Cetuximab with
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab with oral sorafenib
Study: 19064532
Drug: Cocoa treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa treatment (150 mL twice a day, approximately 900 mg flavanols/d)
Study: 19064532
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (approximately 28 mg flavanols/d)
Study: 15767642
Drug: Combination (Anastrozole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (Anastrozole + Tamoxifen)
Study: 10864051
Drug: Dexamethasone at
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone at a dose of 6 mg/m2 per day (standard risk) or 18 mg/m2 per day (high risk)
Study: 10864051
Drug: Prednisone at
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone at a dose of 40 mg/m2/d (standard risk) or 120 mg/m2/d (high risk)
Study: 29481452
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (6 mg·kg)
Study: 24793028
Drug: Mesalamine dose
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine dose escalation (2.4 g/day increase for 6 weeks)
Study: 24793028
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued current dose of mesalamine)
Study: 24793028
Drug: Mesalamine dose
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine dose escalation
Study: 24793028
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with FC >200 μg/g
Study: 11524326
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block with 1.5% mepivacaine (40 mL) followed by a postoperative intraarticular infusion of 0.5% ropivacaine at 2 mL/h
Study: 11524326
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block with 0.5% ropivacaine (40 mL) followed by a postoperative intraarticular infusion of 0.9% saline (placebo) at 2 mL/h
Study: 8237931
Drug: iv metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv metoclopramide (20‐mg bolus)
Study: 20518170
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (Ximen (PC 4), Yinxi (HT 6), Xuehai (SP 10), Zhaohai (KI 6)) for 10 days
Study: 20518170
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Carbamazepine) for 10 days
Study: 12742991
Drug: Troglitazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (600 mg/day for 12 weeks)
Study: 9085015
Drug: Dexniguldipine (DNIG)
DrugBank: Dexniguldipine (DB14068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexniguldipine (DNIG) 1-11 mg/kg/4h infusion
Study: 9085015
Drug: Vinblastine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine 0.15 mg/kg
Study: 9085015
Drug: Long-term infusion
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term infusion of DNIG (5 and 7 mg/kg/24h)
Study: 9085015
Drug: DNIG infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNIG infusion (5 and 7 mg/kg/4h)
Study: 9085015
Drug: DNIG infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNIG infusion
Study: 10920613
Drug: Mycobacterium w
Normalized name: Mycobacterium W Vaccine
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium w vaccine
Study: 29490024
Drug: Granulocyte/Monocyte Apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte/Monocyte Apheresis (GMA) plus oral prednisone (40 mg/day and tapering)
Study: 11043499
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone alone
Study: 29490024
Drug: Granulocyte/Monocyte Apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte/Monocyte Apheresis (GMA) plus oral prednisone (GMA group)
Study: 16405522
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy based on BNP levels
Study: 16405522
Drug: BNP cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP cut-off level of 1.25 pmol L(‐1)
Study: 7680832
Drug: Synthetic porcine
Normalized name: Secretin synthetic porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic porcine galanin (0.5 mg in 100 ml saline)
Study: 7680832
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (100 ml saline)
Study: 3554804
Drug: Bencyclane 200
Normalized name: bencyclane 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencyclane 200 mg b.i.d.
Study: 29708822
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg TID for 2 weeks (open-label treatment)
Study: 29708822
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg TID for 2 weeks (double-blind treatment)
Study: 29708822
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 2 weeks (double-blind treatment)
Study: 24167181
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to polyalkyloxy compounds used as adjuvants
Study: 19186725
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion treatment
Study: 19563205
Drug: Routine medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medicine treatment
Study: 17417987
Drug: Oxaceprol 1200
Normalized name: Oxaceprol
DrugBank: Oxaceprol (DB13363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaceprol 1200 mg/day
Study: 15351584
Drug: Unilateral pudendal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral pudendal nerve blockade with 10 mg of 1% prilocaine (group 1, n = 26)
Study: 15351584
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control with 10 mL of 0.9 NaCl solution (group 2, n = 25)
Study: 9566835
Drug: Gamma-linolenic and
Normalized name: gamma-linolenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-linolenic and linoleic acid (1 g/day of each fatty acid) for 6 weeks
Study: 7997384
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg with concomitant ddI 300 mg
Study: 2454893
Drug: Pseudomonas aeruginosa
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine
Study: 2454893
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of vaccine at 15 months
Study: 31479007
Drug: Information only
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information only control group (monthly newsletters on type 2 diabetes education and prevention)
Study: 25869875
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (90 min, twice a week for 12 weeks)
Study: 15893416
Drug: Imatinib (2x400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (2x400 mg po daily)
Study: 15893416
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2 weekly)
Study: 16508584
Drug: Hormonal replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal replacement therapy (HRT)
Study: 9359745
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy (zidovudine, didanosine, nevirapine)
Study: 8229656
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) treatment group
Study: 8229656
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) treatment group
Study: 6495086
Drug: Gallbladder contraction
Normalized name: Bos taurus gallbladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallbladder contraction stimulated by intravenous pancreozymin
Study: 31300280
Drug: Advax-adjuvanted honeybee
Normalized name: Tdvax
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advax-adjuvanted honeybee venom immunotherapy (HBVIT)
Study: 31300280
Drug: Honeybee venom
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honeybee venom immunotherapy (VIT) without Advax adjuvant
Study: 24964759
Drug: Intravenous CCRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CCRT (n = 80)
Study: 15486066
Drug: MTX-4h (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX-4h (methotrexate as intravenous infusion over 4 hours)
Study: 15486066
Drug: MTX-24h (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX-24h (methotrexate as intravenous infusion over 24 hours)
Study: 15486066
Drug: MTX 1
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 1 g/m(2) (in NHL-BFM95)
Study: 15486066
Drug: MTX 5
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 5 g/m(2) (in NHL-BFM90)
Study: 11443161
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug pretreatment
Study: 2511910
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 200 mg three times daily
Study: 1127088
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg calcium/kg (calcium gluconate at 3 ml/min for 3 h followed by normal saline for the fourth hour)
Study: 1127088
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline at 3 ml/min for 4 h
Study: 1127088
Drug: l-dopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-dopa (500 mg oral dose) during normal saline and calcium infusions
Study: 28816033
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg bilayer sustained-release acetaminophen (APAP)
Study: 28816033
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg immediate-release acetaminophen (APAP) taken 6 hours apart
Study: 28816033
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg single-layer sustained-release acetaminophen (APAP)
Study: 28816033
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg single-layer sustained-release acetaminophen (APAP) with different excipient
Study: 28816033
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg enteric-coated sustained-release acetaminophen (APAP) with fast-dissolving IR APAP
Study: 24114402
Drug: High-dose intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intervention (HI) group
Study: 23176993
Drug: Levobupivacaine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 5% administered over 1 min (fast) in Group F
Study: 23176993
Drug: Levobupivacaine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 5% administered over 3 min (slow) in Group S
Study: 18691986
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of ketotifen fumarate ophthalmic solution 0.025%
Study: 18691986
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of ketotifen fumarate ophthalmic solution 0.025%
Study: 1800929
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% cyclosporine
Study: 22315155
Drug: leuprolide 3.75
Normalized name: leuprolide 3.75 mg intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: leuprolide 3.75 mg
Study: 22315155
Drug: leuprolide 7.5
Normalized name: leuprolide 7.5 mg/month intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: leuprolide 7.5 mg
Study: 22315155
Drug: goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: goserelin 3.6 mg